NEW
YORK, Dec. 15, 2024 /PRNewswire/ -- The
global gastroparesis drugs market size is estimated to
grow by USD 1.42 billion from 2024 to
2028, according to Technavio. The market is estimated to grow at a
CAGR of 3.69% during the forecast period. The report provides a
comprehensive forecast of key segments below-
Segmentation Overview
- Drug Class
- 1.1 Prokinetic agents
- 1.2 Antiemetics
- 1.3 Botulinum toxin injection
- Disease Type
- 2.1 Idiopathic gastroparesis
- 2.2 Diabetic gastroparesis
- 2.3 Post-surgical gastroparesis
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
Get a glance at the market contribution of rest
of the segments - Download a FREE Sample Report in
minutes!
1.1 Fastest growing segment:
Prokinetic drugs play a significant role in managing
gastroparesis, a condition characterized by delayed stomach
emptying. These medications, such as metoclopramide and
domperidone, are popular due to their ability to address the
fundamental cause of the condition. While not all prokinetic agents
produce a corresponding improvement in stomach emptying, they are
effective in alleviating symptoms like nausea, vomiting, and early
satiety. Other recent drugs, including ghrelin, motilin, 5-HT4
receptor agonists, and dopamine receptor agonists, are being
studied for their potential in gastroparesis treatment. The use of
prokinetic agents for symptoms like constipation, caused by
decreased motility in the distal GI tract, also increases their
demand and drives market growth during the forecast period. Ani
Pharmaceuticals offers Reglan, a metoclopramide formulation, for
gastroparesis treatment in the US.
Analyst Review
Gastroparesis is a chronic condition characterized by delayed
emptying of the stomach, leading to various digestive disruptions
such as nausea, vomiting, and abdominal pain. Neurogastrx's
tradipitant is a promising new drug for gastroparesis treatment,
while metopimazine, deudomperidone, and metoclopramide are common
antiemetics used for symptom management. Evoke Pharma and ANI
Pharmaceuticals are among the companies involved in gastroparesis
drug development. Diabetes, lifestyles including alcohol
consumption and tobacco use, and certain medications like
Erythromcin can trigger gastroparesis. Innovative drugs under
clinical trials aim to address the underlying causes and improve
patient outcomes. However, these drugs may carry risks such as
liver injury, GI bleeding, acute cholecystitis, and acute
pancreatitis. Antiemetics like Reglan have been linked to Tardive
Dyskinesia, a serious side effect. Clinical trials are ongoing to
evaluate the safety and efficacy of new treatments for
gastroparesis.
Market Overview
Gastroparesis is a digestive disorder characterized by delayed
emptying of the stomach. Neurogastrx's tradipitant is a promising
innovative drug under development for gastroparesis treatment.
Other prokinetic agents like metopimazine, deudomperidone, and
metoclopramide are commonly used for symptom management. Evoke
Pharma and ANI Pharmaceuticals are among the companies involved in
gastroparesis drug development. Diabetes, lifestyles (alcohol
consumption, tobacco use), and certain medications can trigger
gastroparesis. Symptoms include nausea, vomiting, abdominal
discomfort, and nutrient absorption complications. Diabetic
gastroparesis is a common complication in diabetic cases. Hospitals
and specialized care centers offer surgical interventions for
severe cases, including FDA-cleared procedures. PubMed Central
hosts numerous studies on gastroparesis, its causes, and potential
treatments. Other conditions like Acute cholecystitis and Acute
pancreatitis can also cause gastroparesis. Antiemetics like
Erythromycin and Reglan are sometimes used to manage symptoms.
Clinical trials are ongoing to explore new treatment options.
Autonomic neuropathy is a potential cause of gastroparesis.
Prokinetic agents help promote stomach contractions and hinder
hindering digestion. Enteral nutrition and feeding intolerance are
common complications.
To understand more about this
market- Download a FREE Sample Report in minutes!
Key Topics Covered:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Venodr Landscape
11 Vendor Analysis
11.1 Medtronic
11.2 Kimberly-Clark Corporation
11.3 Abbott Laboratories
11.4 Salix Pharmaceuticals
11.5 Boston Scientific Corporation
11.6 C. R. Bard
11.7 Janssen Global Services
11.8 Cardinal Health
11.9 Alfa Wassermann
11.10 Evoke Pharma
11.11 Rhythm Pharmaceuticals
11.12 AbbVie
11.13 Aclipse Therapeutics
11.14 ANI Pharmaceuticals
11.15 Bausch Health Companies
11.16 Cadila Pharmaceuticals
11.17 Eisai, GlaxoSmithKline
11.18 Ipca Laboratories
11.19 Johnson and Johnson.
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gastroparesis-drugs-market-size-to-increase-by-usd-1-42-billion-between-2023-to-2028--market-segmentation-by-drug-class-disease-type-geography-technavio-302331403.html
SOURCE Technavio
